论文部分内容阅读
目的：观察尿激酶（ＵＫ）静脉溶栓治疗急性心肌梗塞（ＡＭＩ）的溶栓时机及临床疗效。方法：３９例ＡＭＩ患者，用ＵＫ静脉溶栓治疗，半小时内输注 １００～１５０万单位。结果：①临床判断梗塞相关血管再通２４例，再通率６１．５％；２小时内、２～４小时、４～６小时及６～１２小时内相关血管再通率分别为８０．０％、７２．７％、５７．１％和４４．４％；死亡４例，病死率１０．３％；并发出血３例，出血率７．７％。②溶栓再通患者病死率（４．２％，１／２４）明显低于未通患者（２０．０％，３／１５）。结论：ＵＫ溶栓治疗ＡＭＩ安全有效。
Objective: To observe the timing and clinical effect of intravenous thrombolytic therapy of urokinase (UK) on acute myocardial infarction (AMI). Methods: Thirty-nine patients with AMI were treated with UK intravenous thrombolysis and infused 100 to 1.5 million units in half an hour. Results: ①24 cases of recanalization associated with infarction were clinically diagnosed, and the recanalization rate was 61.5%. The rates of recanalization within 2 hours, 2 to 4 hours, 4 to 6 hours and 6 to 12 hours were 80.0 %, 72.7%, 57.1% and 44.4% respectively; 4 died and the case fatality rate was 10.3%; 3 cases had concurrent bleeding and the bleeding rate was 7.7%. ② The mortality rate of patients receiving thrombolytic recanalization (4.2%, 1/24) was significantly lower than that of patients without recanalization (20.0%, 3/15). Conclusion: UK thrombolytic therapy for AMI is safe and effective.